LACTOLOGY FOUNDATION

Rabeprazole (ATC A02BC04) is a proton pump inhibitor that should be considered contraindicated during breastfeeding, despite expected low milk transfer, because of its toxicological profile and lack of human lactation data. Below is an English toxico‑lactological monograph formatted as web‑page content, aligned with your existing TOXYLACT style.file+4

Pharmacological class and clinical indications

Rabeprazole is a proton pump inhibitor (PPI) within ATC subgroup A02BC, used to suppress gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase in gastric parietal cells. This mechanism produces potent and sustained acid suppression, facilitating healing of acid‑related mucosal lesions and relief of reflux symptoms.atcddd.fhi+4

It is indicated for erosive or ulcerative gastro‑oesophageal reflux disease (GERD), symptomatic GERD, long‑term maintenance therapy in GERD, duodenal and benign gastric ulcers, eradication of Helicobacter pylori (in combination regimens), prevention and treatment of stress ulcers in at‑risk patients, and management of hypersecretory states including Zollinger–Ellison syndrome. PPIs, including rabeprazole, should not be used continuously for more than 8 weeks without re‑evaluation of the indication.laegemiddelstyrelsen+3

General toxicology and adverse effects

Rabeprazole shares the typical PPI adverse‑effect pattern, with common reactions such as headache, dizziness, confusion, gastrointestinal symptoms (nausea, vomiting, diarrhoea, flatulence), abdominal or chest pain, and various skin or hypersensitivity reactions. Less frequent but clinically important toxicities include hypomagnesaemia (which can precipitate or exacerbate digoxin toxicity), acute interstitial nephritis, vitamin B12 deficiency, and bone fractures, particularly of the hip, wrist and spine with long‑term high‑dose use in older patients or those with other risk factors.hpra+2

Rabeprazole therapy can predispose to or worsen Clostridioides difficile–associated diarrhoea and other gastrointestinal infections (e.g. Salmonella, Campylobacter), by reducing gastric acidity and increasing bacterial colonisation of the upper gastrointestinal tract. Regulatory documents and TOXYLACT emphasise experimental carcinogenicity signals for rabeprazole in animal studies and possible links to MALT lymphoma after prolonged use beyond 12 months, supporting a cautious toxicological stance. In children under 3 years, long‑term rabeprazole therapy may increase the risk of vitamin B12 deficiency and related haematological or neurological consequences.file+2

Drug interactions and pharmacokinetics

Rabeprazole is highly unstable in the acidic gastric lumen, so it is formulated as enteric‑coated or controlled‑release tablets to ensure intact passage through the stomach and release in the intestine. After oral administration, approximately 52% of the dose is absorbed, with about 96% plasma protein binding; the plasma half‑life is 1–2 hours, while the pharmacodynamic effect on acid secretion persists for more than 24 hours after discontinuation.pharm.cals+2

Rabeprazole undergoes extensive hepatic metabolism via CYP450 isoenzymes, leading to numerous clinically relevant interactions. It can potentiate the effects or toxicity of diazepam, fluazepam, digoxin, cyclosporine, tacrolimus, certain antifungals, some new oral anticoagulants, and protease inhibitors such as saquinavir. It reduces gastrointestinal absorption of ketoconazole, itraconazole, ampicillin, oral iron preparations, and mycophenolate mofetil, potentially diminishing their therapeutic effects. Conversely, rabeprazole may decrease the efficacy of atazanavir, nelfinavir, clopidogrel, and rifampicin via gastric pH elevation and/or hepatic metabolic interference.midlandsmedicines+3

Pregnancy risk

There are no adequate data on the safety of rabeprazole in human pregnancy, and regulatory documentation explicitly states that rabeprazole is contraindicated during pregnancy. In TOXYLACT, rabeprazole is assigned FDA pregnancy category C, reflecting animal toxicity and lack of robust human data, and thus should not be used in pregnant women except in rare, strictly justified circumstances. When acid‑suppressive therapy is required in pregnancy, safer alternatives with more data (e.g. antacids, alginates, H2‑receptor antagonists, and better‑studied PPIs such as omeprazole) are preferred.pmc.ncbi.nlm.nih+4

Lactation pharmacokinetics

Rabeprazole sodium has a molecular weight around 381 Da, which by itself would allow passage into breast milk, but its very high plasma protein binding substantially limits the fraction that can be excreted. Lactation resources note that no direct human milk data are available, yet the physicochemical properties of rabeprazole predict low milk concentrations. Any rabeprazole that reaches milk would be ingested without an enteric coating and subjected to the infant’s gastric acid, which is expected to degrade the molecule and greatly reduce systemic absorption.sps+3

Despite this, TOXYLACT stresses that animal experiments have demonstrated pronounced carcinogenic potential of rabeprazole, and therefore even minimal infant exposure via breast milk is considered unacceptable. Consistent with this, the European risk management plan and product information report that it is unknown whether rabeprazole is excreted into human breast milk and explicitly advise that rabeprazole should not be used during breastfeeding.laegemiddelstyrelsen+2

Lactation safety classification and clinical recommendations

Specialist breastfeeding guidance for PPIs recognises that there are no milk level data for rabeprazole and recommends omeprazole or pantoprazole as preferred PPIs in lactating women, based on measurable low milk levels and reassuring infant outcomes. While some secondary lactation sources rate rabeprazole as “very low risk” or “compatible” by extrapolation from class properties, they still emphasise the lack of direct human evidence and the need to consider safer alternatives.e-lactation+3

In TOXYLACT, rabeprazole is assigned Toxico‑lactation category IV: not compatible with breastfeeding; its use during lactation is not recommended. For toxico‑lactological practice, rabeprazole should be avoided in all breastfeeding women, regardless of infant age, and therapy should be switched to PPIs with documented low milk transfer and safer profiles (omeprazole or pantoprazole) or to non‑PPI options where clinically feasible. If a woman has been inadvertently exposed to rabeprazole during breastfeeding, the infant should be monitored for gastrointestinal symptoms, poor weight gain, or unusual lethargy, and the need for continued therapy should be urgently reassessed.pubmed.ncbi.nlm.nih+4

Toxico‑lactation category (TOXYLACT style proposal)

• Toxico‑lactation category IV: Rabeprazole is not compatible with breastfeeding; its use is contraindicated in lactating women and a safer alternative should be chosen.sps+3
• Breastfeeding or rabeprazole therapy should be discontinued if rabeprazole is deemed absolutely necessary, with clear documentation of the risk–benefit analysis.midlandsmedicines+2

Role within TOXYLACT and lactology practice

The Lactology Foundation’s TOXYLACT database aims to support a lower‑toxic world and healthier breastfed infants by systematically analysing toxicity and lactation risk for medicinal products. The rabeprazole entry combines pharmacology, adverse‑effect profile, interaction data, pregnancy risk categorisation, and lactation pharmacokinetics, integrating regulatory documents and specialist breastfeeding guidance to reach a cautious, protection‑oriented conclusion.file+3

Within clinical lactology, rabeprazole serves as an illustrative example of a drug whose expected low milk transfer does not automatically translate into acceptability, due to significant toxicological concerns and missing human data; this underlines the need to evaluate both exposure and intrinsic hazard when advising breastfeeding women.e-lactation+2